News

BIO: debating value in Chicago
Enlarge image

BusinessEU

BIO: debating value in Chicago

25.04.2013 - At the BIO International convention in Chicago, analysts have reported strong performance from the global biotech sector.

They pointed out that there is an urgent need for the industry to demonstrate value of products under development. For 2012, Ernst & Young’s industry report “Beyond borders” reports an increase in revenues by 8% to US$ 89.8bn, with the net income of US$5.2 bn, representing a record high. In Europe, revenues of public biotechs grew 8% to US$ 20.4bn. However, R&D expense decreased by 1 %, which is regarded as an indication that the firms remain in a cost-cutting mode. 

A new survey amongst small and mid-size companies has revealed an “implementation gap” when it comes to gathering evidence to demonstrate the value of products at early stages of development. “Biotech companies can no longer afford to pursue an R&D strategy that only focuses on whether or not their drug works”, said Gautam Jaggi from the Ernst &Young Global Life Sciences Center. Strategic investors and pharma alliance partners would now consider such data to be key drivers of their product and company valuations. “Companies cannot afford not to rethink their R&D approaches and to invest in addressing questions of value”, he said. 

In his talk, Steven Burrill presented similar view. The life science industry insider said in his “supersession”, that value of products is not a constant. “Instead, companies will need to be prepared to prove the value of their products in a world where value is transient, value is payer dependent and value is geographically different“, he said. And, as pressures on pricing intensify, companies will need to be creative in forging new ways to capture value. “Value, like beauty,”  Burrill said, “is in the eye of the beholder.” Companies should have that in mind very early in development.  Celebrating its 20th birthday, BIO International Convention was held in Chicago this year. The most important event for the global biotech industry has attracted over 2000 exhibitors this year, and will see more than 25.000 partnering meetings. 

© eurobiotechnews.eu/pg

BusinessSpainUKSweden

31.07.2014 Astrazeneca is buying the rights to Almirall’s respiratory drugs in a deal worth up to €1.56bn.

BusinessFranceGermanySwitzerlandUK

30.07.2014 Rumours have it that French Danone wants to sell its medical nutrition business to US drugmaker Hospira for US$5bn in yet another tax inversion deal.

RegulationUKEU

29.07.2014 The first vaccine for malaria may be within reach: The European Medicines Agency has accepted Glaxosmithkline’s malaria vaccine candidate RTS,S for regulatory review.

FundingEU

25.07.2014 The European Commission aims to support innovation in Europe and announced a "Fast Track to Innovation" pilot as well as five innovation prices under Horizon 2020.

ResearchUKEU

23.07.2014 In the largest genomic study published on any psychiatric disorder so far, researchers have indentified 83 new locations in the human genome associated with the risk of developing schizophrenia.

BusinessUKIreland

21.07.2014 Abbvie’s tenacious pursuit of British rival Shire is finally paying off: The two companies have unveiled their transatlantic merger worth £32bn (€40bn).

ResearchEUSwitzerland

17.07.2014 A trans-border, cross-disciplinary project that aims to model the human brain in a computer has drawn heavy criticism from scientists pledging to boycott the project.

MergerUK

16.07.2014 After rejecting three merger propositions from US competitor Abbvie, Shire has now given up resistance to the deal and is recommending a new and improved offer worth £31.3bn.

AcquisitionUKDenmarkSpainGermanyFrance

15.07.2014 British specialty pharma company Prostrakan is handing over £230m for Archimedes Pharma Limited, a company that brings its lead product Pecfent and its proprietary drug delivery technology platform into the deal.

FundingEU

11.07.2014 Among the seven newly launched Joint Technology Initiatives (JTI) of Horizon2020 are two with deep roots in biotech: IMI is going into its second round while the newly established Bio-based Industries partnership invests in bioeconomy.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • NOVACYT (F)4.97 EUR11.43%
  • PROSENSA (NL)10.24 USD5.89%
  • NEUROVIVE PHARMACEUTICAL AB (S)74.00 SEK5.71%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • STENTYS (F)7.26 EUR-12.32%

TOP

  • WILEX (D)2.70 EUR229.3%
  • NEUROVIVE PHARMACEUTICAL AB (S)74.00 SEK52.6%
  • Allergy Therapeutics (UK)20.00 GBP34.4%

FLOP

  • HYBRIGENICS (F)1.68 EUR-29.7%
  • GW PHARMACEUTICALS (UK)418.50 GBP-20.1%
  • PHARMING (NL)0.44 EUR-20.0%

TOP

  • SANTHERA (CH)59.90 CHF2836.3%
  • GW PHARMACEUTICALS (UK)418.50 GBP634.2%
  • PAION (D)2.50 EUR284.6%

FLOP

  • EVOCUTIS (UK)0.21 GBP-92.7%
  • CYTOS (CH)0.27 CHF-92.0%
  • THROMBOGENICS (B)9.16 EUR-70.3%

No liability assumed, Date: 31.07.2014